ʻO Semaglutide kahi polypeptide i kuhikuhi ʻia e nā kauka no ka mālama ʻana i ka maʻi diabetes type 2.Ua ʻae ka FDA i ka hoʻohana ʻana iā Novo Nordisk's Ozempic a me Rybelsus i hoʻokahi pule i hoʻokahi pule a i ʻole he papa.Ua ʻae hou ʻia kahi hoʻokele o ka semaglutide i hoʻokahi pule i kēlā me kēia pule me ka inoa inoa ʻo Wegovy ma ke ʻano he lāʻau hoʻēmi kaumaha.
ʻO ka noiʻi hou i hōʻike ʻia ma ka European Congress on Obesity o kēia makahiki (ECO2023, Dublin, 17-20 Mei) e hōʻike ana i ka maikaʻi o ka lāʻau obesity semaglutide no ka pohō kaumaha ma kahi multicenter, 1 makahiki lōʻihi o ka honua maoli.ʻO ke aʻo ʻana e Dr Andres Acosta a me Dr Wissam Ghusn, Precision Medicine for Obesity Program ma ka Mayo Clinic, Rochester, MN, USA a me nā hoa hana.
ʻO Semaglutide, he glucagon-like peptide-1 (GLP-1) receptor agonist, ʻo ia ka lāʻau lapaʻau anti-obesity hou loa i ʻae ʻia e FDA.Ua hōʻike i nā hopena hoʻemi koʻikoʻi i loko o nā hoʻokolohua hoʻokolohua hoʻokolohua lōʻihi lōʻihi a me nā noiʻi honua maoli.Eia naʻe, liʻiliʻi ka ʻike e pili ana i ka pohō kaumaha a me nā hopena metabolic ma waena o nā haʻawina honua maoli.Ma kēia haʻawina, ua loiloi nā mea kākau i nā hopena o ka pohō kaumaha e pili ana me ka semaglutide i nā maʻi me ka momona a me ka momona me ka ʻole o ka maʻi diabetes type 2 (T2DM) ma ka 1 makahiki hahai.
Ua hana lākou i kahi retrospective, multicentre (Mayo Clinic Hospitals: Minnesota, Arizona, a me Florida) hōʻiliʻili ʻikepili i ka hoʻohana ʻana i ka semaglutide no ka mālama ʻana i ka momona.Hoʻokomo lākou i nā maʻi me ka helu kino kino (BMI) ≥27 kg/m2 (ke kaumaha a me nā ʻāpana BMI kiʻekiʻe aʻe) i kuhikuhi ʻia i kēlā me kēia pule semaglutide subcutaneous injections (doses 0.25, 0.5, 1, 1.7, 2, 2.4mg; ʻO ka nui kiʻekiʻe he 2.4mg).Hoʻokuʻu lākou i nā poʻe maʻi e lawe ana i nā lāʻau ʻē aʻe no ka momona, ka poʻe me ka mōʻaukala o ka ʻoki ʻana i ka momona, ka poʻe me ka maʻi kanesa, a me ka poʻe hāpai.
ʻO ka helu hope mua ʻo ia ka nui o ke kaumaha o ke kino (TBWL%) ma 1 makahiki.Loaʻa nā helu hope lua i ka māhele o nā maʻi e loaʻa ana i ka ≥5%, ≥10%, ≥15%, a me ≥20% TBWL%, hoʻololi i nā ʻāpana metabolic a me ka cardiovascular (ke koko, HbA1c [glycated hemoglobin, kahi ana o ka hoʻomalu ʻana i ke kō koko], ka hoʻokēʻai glucose a me nā momona koko), TBWL% o nā maʻi me ka T2DM a me ka ʻole, a me ka pinepine o nā hopena ʻaoʻao i ka makahiki mua o ka lāʻau lapaʻau.
ʻO ka nui o nā maʻi 305 i hoʻokomo ʻia i ka loiloi (73% wahine, mean makahiki 49 makahiki, 92% keʻokeʻo, ʻo ia hoʻi ka BMI 41, 26% me T2DM).Hōʻike ʻia nā hiʻohiʻona kumu a me nā kikoʻī kipa mālama paona ma ka Papa 1 piha piha.Ma ka hui holoʻokoʻa, ʻo ka TBWL% mean he 13.4% i ka makahiki 1 (no nā maʻi 110 i loaʻa ka ʻikepili kaumaha ma 1 makahiki).ʻO nā maʻi me T2DM he TBWL% haʻahaʻa o 10.1% no nā maʻi 45 o 110 me ka ʻikepili ma 1 makahiki, hoʻohālikelike ʻia me ka poʻe me ka T2DM o 16.7% no nā maʻi 65 o 110 me ka ʻikepili i ka makahiki 1.
ʻO ka pakeneka o nā maʻi i nalowale ma mua o 5% o ko lākou kaumaha kino he 82%, ʻoi aku ma mua o 10% he 65%, ʻoi aku ma mua o 15% he 41%, a ʻoi aku ma mua o 20% he 21% i ka makahiki 1.ʻO ka mālama ʻana iā Semaglutide i hoʻemi nui i ke koko systolic a me ka diastolic e 6.8/2.5 mmHg;huina cholesterol ma ka 10.2 mg/dL;LDL o 5.1 mg/dL;a me nā triglycerides o 17.6 mg/dL.ʻO ka hapalua o nā maʻi i loaʻa i nā hopena ʻaoʻao e pili ana i ka hoʻohana ʻana i ka lāʻau lapaʻau (154/305) me ka hapa nui o ka nausea (38%) a me ka maʻi maʻi (9%) (Figure 1D).ʻO nā hopena ʻaoʻao he haʻahaʻa loa ʻaʻole i pili i ka maikaʻi o ke ola akā i nā hihia 16 ua hopena lākou i ka hoʻōki ʻana i ka lāʻau lapaʻau.
Hoʻopau nā mea kākau: "Ua pili ʻo Semaglutide i ka nui o ke kaumaha a me ka hoʻomaikaʻi ʻana i nā ʻāpana metabolic i ka makahiki 1 i kahi noiʻi honua maoli, e hōʻike ana i kona pono i ka mālama ʻana i ka momona, i nā maʻi me ka T2DM ʻole."
Ke hoʻomākaukau nei ka hui Mayo i kekahi mau manuscripts e pili ana i ka semaglutide, me nā hopena kaumaha i nā maʻi i loaʻa ke kaumaha ma hope o ke kāʻei bariatric;nā hopena hoʻemi kaumaha i nā maʻi i loaʻa i nā lāʻau anti-obesity i hoʻohālikelike ʻia i ka poʻe ʻaʻole.
Ka manawa hoʻouna: Sep-20-2023